Mekinist (trametinib) - Novartis, BeOne Medicines
Preoperative classification using integrated screening and short-course neoadjuvant BRAF/MEK inhibition in newly diagnosed papillary craniopharyngioma (the PRECISE-PCP study): a prospective single-arm study (ChiCTR) - Oct 16, 2026 - P2 | N=12 | Recruiting | Sponsor: Huashan Hospital, Fudan University; Huashan Hospital, Fudan University | Not yet recruiting ➔ Recruiting | Phase classification: PN/A ➔ P2 
Enrollment open • Phase classification • Brain Cancer • CNS Tumor
https://www.chictr.org.cn/showproj.html?proj=222170
 
Oct 16, 2026
 
Prev Next